Human urine extract can also treat stroke

Acute stroke (commonly known as stroke) is one of the acute and critical medical diseases It has high incidence rate, high disability rate and poor prognosis Whether treatment is timely, reasonable and directly affects the prognosis of patients If the standardized treatment can be carried out in the early stage of stroke, the disease will be controlled and the patient's life will be more guaranteed Professor Hu Xueqiang, director of Neurology Department of the Third Affiliated Hospital of Sun Yat sen University, introduced that the treatment of acute ischemic stroke with kininogenase is one of the hot spots of international research in the past 20 years Human urinary kallidinogenase is a glycoprotein extracted from human urine, which can activate the conversion of human plasma kallidinogenase into kallidinogenase, so as to selectively expand the blood vessels in the focus area, improve the effect of blood circulation, increase the deformability of red blood cells, inhibit platelet aggregation, and can be used for the treatment of acute ischemic stroke It is understood that in order to standardize the diagnosis and treatment of acute ischemic stroke and the prevention of ischemic stroke, the cerebrovascular group of Neurology branch of Chinese Medical Association issued the guidelines for the diagnosis and treatment of China's acute ischemic stroke and the guidelines for the secondary prevention of China's ischemic stroke / transient ischemic attack (hereinafter referred to as the guidelines) The position of human urinary kallidinogenase in the guide is gradually promoted In the 2010 edition of the guide, human urinary kallidinogenase is only written in other therapeutic parts In the 2014 version of the guide, it is clear that human urinary kallidinogenase is a drug that can improve cerebral blood circulation (Level II recommendation, level B evidence), and as one of the specific treatment programs This is mainly because the results of clinical multicenter, double-blind and placebo-controlled trials show that the functional outcome of human urinary kallidinogenase is significantly improved and safe than that of placebo group, and its efficacy is recognized in clinical practice and its status is improved Professor Hu Xueqiang pointed out that human urinary kallidinogenase can significantly improve the degree of neurological deficit and the ability of daily life activities of patients, reduce the mortality and disability rate of patients with acute ischemic stroke, significantly improve the prognosis and quality of life of patients, so as to reduce the burden of society and patients' families Professor Hu Xueqiang said that in addition to the standardization of clinical and drug treatment, stroke patients should also strengthen the prevention and control of risk factors, especially the individualization of prevention and control measures to achieve the combination of common and individual measures, so as to achieve the best prevention and control effect Specific measures include: active treatment and control of hypertension; strengthening the treatment of diabetes, heart disease and blood system diseases; strengthening physical exercise; reasonable diet, appropriate intake of animal protein, such as lean meat, fish, poultry, etc.; reducing salt intake, controlled within 6 grams per day; increasing fresh fruits and vegetables to increase potassium intake; advocating smoking cessation, weight control, Du Absolutely bad way of life.